NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$3.46
0.08 (2.37%)
▲
5d:
+0.87%
30d:
-5.46%
90d:
-23.79%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 16.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 16.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.23
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.97
50.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $3.46, which is considered slightly low relative to its 30-day fair value range of $3.41 to $3.73. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.1) compared to its historical average (18.9). Remarkably, the market is currently pricing in an annual earnings decline of 16.2% over the next few years. This pessimistic expectation contrasts with the company's recent 16.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NAGE is in a strong downtrend. Immediate support is located at $3.35, while resistance sits at $4.03.
Market Sentiment: NAGE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $12.60 (+272.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAGE is in a strong downtrend. Immediate support is located at $3.35, while resistance sits at $4.03.
Market Sentiment: NAGE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $12.60 (+272.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.41 -
$3.73
Company Quality Score
55/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
73.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 272.8% below Wall St target ($12.60)
Trading Range Analysis
30-Day Trading Range
$3.41 -
$3.73
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.94
(27.1%)
Support & Resistance Levels
Support Level
$3.35
Resistance Level
$4.03
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.08
Wall Street Target
$12.60
(+272.8%)
Revenue Growth (YoY)
3.3%
Earnings Growth (YoY)
16.7%
Profit Margin
14.3%
Valuation Discount vs History
-16.2% cheaper
PE vs Historical
11.1 vs 18.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.2%
(market-implied from PE analysis)
1-Year Target
$3.04
(-10%)
2-Year Target
$2.74
(-19%)
3-Year Target
$2.46
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→19)
$4.20
(+24%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 32.6%)
$15.49
(+358%)
Base:
(SPY PE: 11.1, Growth: 32.6%)
$7.88
(+133%)
Bear:
(PE: 9.4, Growth: 32.6%)
$6.70
(+98%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 16.24 | Current EPS (TTM): $0.21
Bull Case
$5.45
(+61%)
Analyst growth 45.2%, PE expands to 17.9
Base Case
$4.95
(+47%)
Market implied 45.2%, PE stable at 16.2
Bear Case
$2.32
(-31%)
Severe decline -20.0%, PE contracts to 13.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.1 to 18.9
Stabilization Target:
$5.76
(+70.5%)
PE Expansion Potential:
+70.5%
Share & Embed Analysis
Last updated: June 24, 2026 2:52 PM ET
Data refreshes hourly during market hours. Next update: 3:52 PM
Data refreshes hourly during market hours. Next update: 3:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
